Review
doi: 10.1017/S1041610212002414.
Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease
- PMID: 23422014
- DOI: 10.1017/S1041610212002414
Item in Clipboard
Review
Low dose, high dose, or no dose: better prescribing of cholinesterase inhibitors for Alzheimer's disease
Int Psychogeriatr.
2013 Apr.
Free article
No abstract available
Similar articles
-
[Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].MMW Fortschr Med. 2010 Sep 16;152(37):40-1. MMW Fortschr Med. 2010. PMID: 21192453 German. No abstract available.
-
High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease.J Clin Psychiatry. 2014 Mar;75(3):288. doi: 10.4088/JCP.13l08730. J Clin Psychiatry. 2014. PMID: 24717382 Clinical Trial. No abstract available.
-
Student pharmacists: don't forget the product labeling.J Am Pharm Assoc (2003). 2008 Nov-Dec;48(6):696, 700. doi: 10.1331/JAPhA.2008.08057. J Am Pharm Assoc (2003). 2008. PMID: 19019796 No abstract available.
-
Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.CNS Drugs. 2007;21(11):957-65. doi: 10.2165/00023210-200721110-00007. CNS Drugs. 2007. PMID: 17927299 Review. No abstract available.
-
Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.Drugs Aging. 2011 Nov 1;28(11):927-30. doi: 10.2165/11207090-000000000-00000. Drugs Aging. 2011. PMID: 22054233 Review.
Cited by
-
A phase 2 randomized, controlled trial of the α7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia.Alzheimers Dement (N Y). 2015 Jun 23;1(1):81-90. doi: 10.1016/j.trci.2015.06.001. eCollection 2015 Jun. Alzheimers Dement (N Y). 2015. PMID: 29854928 Free PMC article.
-
Primary prevention of Alzheimer's disease: is it an attainable goal?J Korean Med Sci. 2014 Jul;29(7):886-92. doi: 10.3346/jkms.2014.29.7.886. Epub 2014 Jul 11. J Korean Med Sci. 2014. PMID: 25045219 Free PMC article. Review.
-
Pathophysiological Aspects and Therapeutic Armamentarium of Alzheimer's Disease: Recent Trends and Future Development.Cell Mol Neurobiol. 2023 Nov;43(8):3847-3884. doi: 10.1007/s10571-023-01408-7. Epub 2023 Sep 19. Cell Mol Neurobiol. 2023. PMID: 37725199 Free PMC article. Review.
-
ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.Alzheimers Res Ther. 2016 Oct 18;8(1):44. doi: 10.1186/s13195-016-0210-1. Alzheimers Res Ther. 2016. PMID: 27756421 Free PMC article. Clinical Trial.
-
Souvenaid®: a new approach to management of early Alzheimer's disease.J Nutr Health Aging. 2014 Mar;18(3):291-9. doi: 10.1007/s12603-013-0411-2. J Nutr Health Aging. 2014. PMID: 24626757
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
